{"product_id":"mnpr-vrio-analysis","title":"Monopar Therapeutics Inc. (MNPR): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Monopar Therapeutics Inc. (MNPR) truly built to last? This VRIO analysis distills their entire competitive strategy into four critical questions: Value, Rarity, Inimitability, and Organization. Dive in now to see precisely where their sustainable advantage lies - or where it might be vulnerable.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eMonopar Therapeutics Inc. (MNPR) - VRIO Analysis: 1. Late-Stage Asset: ALXN1840 for Wilson Disease\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at Monopar Therapeutics Inc.’s ALXN1840, and the story here is about de-risking a late-stage asset for a rare condition, Wilson Disease. The takeaway is that the imminent regulatory filing, backed by recent positive data, gives them a clear, near-term advantage that’s hard to replicate right now.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Near-Term Revenue Potential\u003c\/h3\u003e\n\u003cp\u003eThis asset, which Monopar Therapeutics in-licensed from Alexion Pharmaceuticals, offers a very tangible path to revenue. They are actively preparing the New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) targeted for \u003cstrong\u003eearly 2026\u003c\/strong\u003e. This timing is key; it means commercialization could start soon after. To support this, as of September 30, 2025, the company had \u003cstrong\u003e$143.7 million\u003c\/strong\u003e in cash, cash equivalents, and investments, which they project will cover operations through at least \u003cstrong\u003eDecember 31, 2027\u003c\/strong\u003e. That runway is defintely enough to get the NDA filed and through initial review. Analyst estimates peg the potential peak sales for ALXN1840 around \u003cstrong\u003e$500 million\u003c\/strong\u003e, which would be transformative for a company with a Q3 2025 net loss of \u003cstrong\u003e$3.4 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: Clinical Data Milestones\u003c\/h3\u003e\n\u003cp\u003eFinding a drug candidate this far along - effectively Phase 3-ready - for a niche indication like Wilson Disease is uncommon. What makes it rarer is the quality of the data package they’ve assembled. Monopar Therapeutics presented compelling new data from the Phase 2 ALXN1840-WD-204 copper balance study at the American Association for the Study of Liver Diseases (AASLD) meeting in \u003cstrong\u003eNovember 2025\u003c\/strong\u003e. This data, showing a rapid and sustained improvement in daily copper balance in the \u003cstrong\u003eeight\u003c\/strong\u003e treated patients, adds significant weight. It’s not just a pre-clinical hope; it’s validated, late-stage data.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: Regulatory Hurdles and Data Ownership\u003c\/h3\u003e\n\u003cp\u003eTrying to copy this asset isn’t just about synthesizing the molecule; it’s about replicating the entire regulatory and clinical journey. Imitating the clinical data package, which includes long-term efficacy and safety data presented at both the European Association for the Study of the Liver (EASL) Congress in \u003cstrong\u003eMay 2025\u003c\/strong\u003e and the American Neurological Association (ANA) meeting in \u003cstrong\u003eSeptember 2025\u003c\/strong\u003e, is incredibly difficult and time-consuming. Plus, Monopar Therapeutics now owns the Investigational New Drug (IND) application, which was officially transferred from Alexion Pharmaceuticals on \u003cstrong\u003eJune 6, 2025\u003c\/strong\u003e. That transfer and the subsequent FDA acknowledgment are administrative hurdles competitors can’t just skip over.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Focused Execution\u003c\/h3\u003e\n\u003cp\u003eThe company is clearly organized around making this submission happen. Their Q3 2025 R\u0026amp;D expenses hit \u003cstrong\u003e$2,589,749\u003c\/strong\u003e, largely driven by manufacturing activities for ALXN1840, showing focused resource allocation. They successfully managed the IND transfer and presented data across multiple major conferences in \u003cstrong\u003e2025\u003c\/strong\u003e to build momentum. This focused execution is what translates a rare asset into a real competitive edge. They know what the next step is.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage: Sustained Lead Time\u003c\/h3\u003e\n\u003cp\u003eThe competitive advantage here is \u003cstrong\u003eSustained\u003c\/strong\u003e, for now. The combination of strong clinical validation and the imminent \u003cstrong\u003eearly 2026\u003c\/strong\u003e NDA filing creates a significant lead time advantage over any potential competitor starting from scratch. They are essentially one filing away from market exclusivity, assuming approval. That head start is gold in biotech.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on the asset’s current standing:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Dimension\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eKey Supporting Data (2025 Fiscal Context)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eNDA filing targeted for \u003cstrong\u003eearly 2026\u003c\/strong\u003e; Cash runway through \u003cstrong\u003eDec 2027\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eRare\u003c\/td\u003e\n\u003ctd\u003eLate-stage asset for rare disease; Positive data presented at \u003cstrong\u003eAASLD Nov 2025\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eDifficult\/Costly\u003c\/td\u003e\n\u003ctd\u003eRequires replicating multi-year clinical data package (e.g., \u003cstrong\u003en=255\u003c\/strong\u003e pooled efficacy).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eOrganized\u003c\/td\u003e\n\u003ctd\u003eFocused spending (Q3 2025 R\u0026amp;D: \u003cstrong\u003e$2.6M\u003c\/strong\u003e); Successful IND transfer completed \u003cstrong\u003eJuly 2025\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eSustained\u003c\/td\u003e\n\u003ctd\u003eImminent regulatory filing creates significant first-mover lead time.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhat this estimate hides is the inherent regulatory risk - the FDA might ask for more data, pushing that \u003cstrong\u003eearly 2026\u003c\/strong\u003e date. Still, the current structure is sound.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eMonopar Therapeutics Inc. (MNPR) - VRIO Analysis: 2. Proprietary Radiopharmaceutical Platform (uPAR-Targeting)\n\u003c\/h2\u003e\n\u003cp\u003e\nh2\u0026gt;Monopar Therapeutics Inc. (MNPR) - VRIO Analysis: 2. Proprietary Radiopharmaceutical Platform (uPAR-Targeting)\n\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eValue:\u003c\/strong\u003e This platform, which includes a proprietary linker technology, allows for targeted delivery of potent radioisotopes, improving the therapeutic index in oncology.\n\u003c\/p\u003e\n\u003cp\u003e\nh3\u0026gt;Value Metrics\n\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated uPAR Expression (Breast Cancer)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e97%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated uPAR Expression (Pancreatic Cancer)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e87%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated uPAR Expression (Colorectal Cancer)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e85%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eRarity:\u003c\/strong\u003e The specific combination of the uPAR target, the pretargeted radioimmunotherapy (PRIT) approach, and the proprietary linker is not common.\n\u003c\/p\u003e\n\u003cp\u003e\nh3\u0026gt;Rarity Indicators\n\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eMNPR-101-Lu Phase 1a trial is active and enrolling in Australia.\u003c\/li\u003e\n\u003cli\u003eThe first patient dosed with MNPR-101-Lu was announced on December 5, 2024, potentially being the world's first dosing of a patient with a uPAR-targeted therapeutic radiopharmaceutical.\u003c\/li\u003e\n\u003cli\u003eMNPR-101-Zr Phase 1 imaging and dosimetry clinical trial is active and enrolling in Australia.\u003c\/li\u003e\n\u003cli\u003eMNPR-101-Ac is in the late preclinical stage.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eImitability:\u003c\/strong\u003e The linker technology, developed in-house or via early academic partnerships, is likely protected by patents, making direct copying hard.\n\u003c\/p\u003e\n\u003cp\u003e\nh3\u0026gt;Imitability\/Intellectual Property\n\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eIP Element\u003c\/th\u003e\n\u003cth\u003eStatus\/Count\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMNPR-101 Patent Portfolio (Total)\u003c\/td\u003e\n\u003ctd\u003eTwo issued U.S. composition of matter and method of use patents, plus allowed applications and pending patents in 22 foreign jurisdictions.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew Linker Family Provisional Patent Filing\u003c\/td\u003e\n\u003ctd\u003eFiled October 2024, covering composition of matter, stability, biodistribution, and versatility with various isotopes\/targeting molecules.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eOrganization:\u003c\/strong\u003e The organization is actively exploiting this by running two concurrent Phase 1\/1a trials (MNPR-101-Zr and MNPR-101-Lu).\n\u003c\/p\u003e\n\u003cp\u003e\nh3\u0026gt;Organizational Exploitation \u0026amp; Financial Capacity\n\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eMNPR-101-Zr Phase 1 (imaging and dosimetry) and MNPR-101-Lu Phase 1a (therapeutic) clinical trials are active and enrolling in Australia.\u003c\/li\u003e\n\u003cli\u003eExpanded Access Program for MNPR-101-Zr and MNPR-101-Lu is active and enrolling in the U.S.\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents and investments as of June 30, 2025: \u003cstrong\u003e$53.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eMonopar expects current funds to be sufficient to continue operations at least through \u003cstrong\u003eDecember 31, 2026\u003c\/strong\u003e, to support the conclusion of the MNPR-101-Zr trial and continuation of the MNPR-101-Lu trial.\u003c\/li\u003e\n\u003cli\u003eResearch \u0026amp; Development expenses for the second quarter of 2025 were \u003cstrong\u003e$1,730,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet loss for the second quarter of 2025 was \u003cstrong\u003e$2.5 million\u003c\/strong\u003e or \u003cstrong\u003e$0.35\u003c\/strong\u003e per share.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. The platform itself is rare, but without a successful Phase 3 readout, competitors can still catch up in the race for uPAR targeting.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eMonopar Therapeutics Inc. (MNPR) - VRIO Analysis: 3. Robust Financial Runway\n\u003c\/h2\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eAs of September 30, 2025, Monopar held $143.7 million in cash, cash equivalents and investments. This balance is expected to fund operations through at least December 31, 2027.\u003c\/p\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eA projected cash runway extending past two years for a clinical-stage firm following a significant capital event in September 2025 represents a strong financial position.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents \u0026amp; Investments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$143.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Operational Runway\u003c\/td\u003e\n\u003ctd\u003eThrough at least \u003cstrong\u003eDecember 31, 2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of Q3 2025 Report\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAggregate Net Proceeds (Offering)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$126.9 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSeptember 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eThe specific quantum and duration of financial security achieved through the September 2025 capital structure is unique to their execution timing.\u003c\/p\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eThe finance team executed the capital raise, which included specific transactions:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eUnderwritten public offering priced on \u003cstrong\u003eSeptember 23, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eAggregate net proceeds from the Offering were approximately \u003cstrong\u003e$126.9 million\u003c\/strong\u003e, before offering expenses and the Share Repurchase.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eNet proceeds after the Share Repurchase were approximately \u003cstrong\u003e$91.9 million\u003c\/strong\u003e, before estimated offering expenses.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$35 million\u003c\/strong\u003e of the Offering proceeds were used to repurchase \u003cstrong\u003e550,229 shares\u003c\/strong\u003e from Tactic Pharma LLC.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eSustained. This financial buffer supports longer-term R\u0026amp;D decisions.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eMonopar Therapeutics Inc. (MNPR) - VRIO Analysis: 4. Active, Multi-Stage Oncology Clinical Trials\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHaving both imaging (MNPR-101-Zr, Phase 1) and therapeutic (MNPR-101-Lu, Phase 1a) trials active de-risks the platform by providing early data on targeting and dosimetry.\u003c\/p\u003e\n\u003cp\u003ePreliminary dosimetry analysis for MNPR-101-Zr showed absorbed organ doses were well below accepted safety limits; for example, the radiation dose to red bone marrow was about \u003cstrong\u003e14 mGy\u003c\/strong\u003e, which is around \u003cstrong\u003e150 times less\u003c\/strong\u003e than the generally accepted limit of \u003cstrong\u003e2-to-3 Gy\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eRunning simultaneous Phase 1 and Phase 1a trials across two different modalities (imaging\/therapy) for the same target is an aggressive, but rare, strategy.\u003c\/p\u003e\n\u003cp\u003eThe first patient was dosed with the therapeutic agent MNPR-101-Lu in early December 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe operational capability to run trials in Australia, combined with the specific protocols, is not easily copied overnight.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe company is organized to manage these complex international trials, having received FDA clearance for the MNPR-101-Lu IND on \u003cstrong\u003eSeptember 26, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eCash, cash equivalents and investments as of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e, were \u003cstrong\u003e$143.7 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe company expects current funds to be sufficient to continue operations at least through \u003cstrong\u003eDecember 31, 2027\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary. Success in these early phases will quickly shift this to sustained, but for now, it’s a race against other uPAR developers.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial Component\u003c\/td\u003e\n\u003ctd\u003eMNPR-101-Zr (Imaging\/Dosimetry)\u003c\/td\u003e\n\u003ctd\u003eMNPR-101-Lu (Therapeutic)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase\u003c\/td\u003e\n\u003ctd\u003ePhase 1\u003c\/td\u003e\n\u003ctd\u003ePhase 1a\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStatus (as of latest report)\u003c\/td\u003e\n\u003ctd\u003eActive and enrolling\u003c\/td\u003e\n\u003ctd\u003eActive and enrolling\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinicalTrials.gov ID\u003c\/td\u003e\n\u003ctd\u003eNCT06337084\u003c\/td\u003e\n\u003ctd\u003eNCT06617169\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eKey operational metrics include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMNPR-101-Zr Phase 1 trial launched in April 2024.\u003c\/li\u003e\n\u003cli\u003eMNPR-101-Lu Phase 1a trial launched in October 2024.\u003c\/li\u003e\n\u003cli\u003ePrimary trial locations are in \u003cstrong\u003eAustralia\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eMonopar Therapeutics Inc. (MNPR) - VRIO Analysis: 5. Strategic In-Licensing Acumen\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The ability to identify, secure, and successfully integrate a late-stage asset like ALXN1840 from a major player like Alexion provides immediate value. The asset completed a pivotal Phase 3 clinical trial that met its primary endpoint, demonstrating that ALXN-1840 cleared copper from tissues \u003cstrong\u003ethree times better\u003c\/strong\u003e than standard-of-care treatments.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Securing exclusive worldwide rights to a Phase 3-ready asset that already met its primary endpoint is a high-value, low-frequency event. This asset was previously acquired by Alexion for $855 million six years prior.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e This depends on the specific deal terms and relationships; the upfront cost was a bargain if the NDA succeeds. The total upfront consideration recorded as IPR\u0026amp;D expense in 2024 was $8.6 million, comprising a $4.0 million cash payment and $4.6 million in equity value.\u003c\/p\u003e\n\n\u003cp\u003eThe structure of the consideration is detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsideration Component\u003c\/td\u003e\n\u003ctd\u003eAmount\/Detail\u003c\/td\u003e\n\u003ctd\u003eTiming\/Basis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Cash Payment\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$4.0 million\u003c\/strong\u003e (Paid as $1.0 million at signing and $3.0 million in January 2025)\u003c\/td\u003e\n\u003ctd\u003eExecution of License Agreement (October 23, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Equity Payment\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e387,329 shares\u003c\/strong\u003e of Common Stock\u003c\/td\u003e\n\u003ctd\u003eRepresented \u003cstrong\u003e9.9%\u003c\/strong\u003e beneficial ownership upon issuance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAggregate Milestone Payments\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$94.0 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eRegulatory approval and sales related\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Sales Royalties\u003c\/td\u003e\n\u003ctd\u003eTiered royalties in the \u003cstrong\u003elow to mid-double digit range\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eUpon commercial sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The leadership team's experience in building companies suggests they know how to structure these value-accretive deals. The company's cash position as of December 31, 2024, was \u003cstrong\u003e$60.2 million\u003c\/strong\u003e, expected to fund operations through at least December 31, 2026, including the ALXN1840 NDA filing.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eDr. Chandler Robinson, Co-Founder and CEO, conducted early research on the drug, leading to its development into ALXN-1840.\u003c\/li\u003e\n\u003cli\u003eDr. Chris Starr, Co-Founder and Executive Chair, co-founded BioMarin and Raptor Pharma, both specializing in orphan drugs.\u003c\/li\u003e\n\u003cli\u003eAlexion is also entitled to receive a percentage in the \u003cstrong\u003emid-double digits\u003c\/strong\u003e of any sublicensing income received by Monopar until the Licensed Product achieves sales.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. This is a one-off win, but the capability to repeat it is a sustained organizational asset.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eMonopar Therapeutics Inc. (MNPR) - VRIO Analysis: 6. Experienced, Lean Management Team\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The leadership team combines scientific depth, evidenced by the CEO holding an M.D., with financial strategy expertise, exemplified by the former CFO bringing over \u003cstrong\u003e20 years\u003c\/strong\u003e of financial strategy, investment, and public company experience.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e The management team exhibits stability with an average tenure of \u003cstrong\u003e6.8 years\u003c\/strong\u003e. The CEO’s total compensation for 2024 was \u003cstrong\u003e$1,144,480\u003c\/strong\u003e, which is below the market average of \u003cstrong\u003e$2.30M\u003c\/strong\u003e for comparable US firms, suggesting cost-conscious leadership.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Deep industry experience and established relationships, built over years of operation, are inherently difficult to replicate quickly.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The team's focus is evidenced by clear milestones set, supported by a balance sheet providing a cash runway extending at least through \u003cstrong\u003eDecember 31, 2026\u003c\/strong\u003e, based on \u003cstrong\u003e$60.2 million\u003c\/strong\u003e in cash, cash equivalents, and short-term investments as of December 31, 2024. Key objectives include assembling a regulatory package and filing an \u003cstrong\u003eNDA for ALXN1840\u003c\/strong\u003e and advancing the \u003cstrong\u003epreclinical MNPR-101-Ac\u003c\/strong\u003e program into the clinic.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. A stable, experienced team navigating complex regulatory paths and managing finite resources to hit critical clinical and regulatory milestones represents a core, hard-to-copy asset.\u003c\/p\u003e\n\u003cp\u003eKey Statistical and Financial Metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eManagement Team Average Tenure\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6.8 years\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRecent Reporting Period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCEO Total Compensation\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1,144,480\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eComparable Market Average CEO Comp.\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.30M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRecent Reporting Period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, \u0026amp; Short-Term Investments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$60.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecember 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Cash Runway End Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eDecember 31, 2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of Q4 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe organization's strategic focus is reflected in the pipeline prioritization:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAdvancing \u003cstrong\u003eMNPR-101-Zr\u003c\/strong\u003e (Imaging Agent) through its first-in-human clinical trial.\u003c\/li\u003e\n\u003cli\u003eContinuing the first-in-human therapeutic clinical trial for \u003cstrong\u003eMNPR-101-Lu\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAdvancing the \u003cstrong\u003eMNPR-101-Ac\u003c\/strong\u003e program, which is in the \u003cstrong\u003elate preclinical stage\u003c\/strong\u003e, into the clinic.\u003c\/li\u003e\n\u003cli\u003eAssembling the regulatory package for \u003cstrong\u003eALXN1840\u003c\/strong\u003e, with a plan to submit the \u003cstrong\u003eNDA for Wilson Disease in early 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eExecutive compensation structure highlights a cost-conscious approach:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCEO total compensation decreased by approximately \u003cstrong\u003e36%\u003c\/strong\u003e from \u003cstrong\u003e$1,778,667\u003c\/strong\u003e in 2023 to \u003cstrong\u003e$1,144,480\u003c\/strong\u003e in 2024.\u003c\/li\u003e\n\u003cli\u003eCOO total compensation decreased by approximately \u003cstrong\u003e39%\u003c\/strong\u003e from \u003cstrong\u003e$911,161\u003c\/strong\u003e in 2023 to \u003cstrong\u003e$554,796\u003c\/strong\u003e in 2024.\u003c\/li\u003e\n\u003cli\u003eThe 2024 compensation structure relied more heavily on base salary and cash bonuses, with \u003cstrong\u003e$0\u003c\/strong\u003e in stock or option awards reported for the CEO in the Summary Compensation Table for 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eMonopar Therapeutics Inc. (MNPR) - VRIO Analysis: 7. Clinical Data Generation \u0026amp; Presentation Cadence\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Regularly presenting high-quality data at major medical meetings builds credibility with regulators and potential partners.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eALXN1840 long-term efficacy and safety data presented at the European Association for the Study of the Liver (“EASL”) International Liver Congress 2025 (May 7 – 10, 2025) as a late-breaker poster presentation.\u003c\/li\u003e\n\u003cli\u003eNew data on long-term neurological efficacy and safety of ALXN1840 presented at the 150th American Neurological Association (ANA) Annual Meeting (September 14-15, 2025).\u003c\/li\u003e\n\u003cli\u003eNew data and analyses from the Phase 2 ALXN1840-WD-204 copper balance study presented at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2025 (November 7-11, 2025).\u003c\/li\u003e\n\u003cli\u003eThe Company is preparing to submit a New Drug Application (“NDA”) to the FDA in early \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e The consistent, high-impact data presentation schedule across both rare disease and oncology programs is a sign of strong clinical execution.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eALXN1840 efficacy data pooled from three clinical trials with \u003cstrong\u003en=255\u003c\/strong\u003e patients; safety analysis included an additional Phase 2 study with \u003cstrong\u003en=266\u003c\/strong\u003e patients.\u003c\/li\u003e\n\u003cli\u003eMedian treatment duration with ALXN1840 was \u003cstrong\u003e961 days\u003c\/strong\u003e (\u003cstrong\u003e2.63 years\u003c\/strong\u003e) for the efficacy dataset.\u003c\/li\u003e\n\u003cli\u003eFewer than \u003cstrong\u003e5%\u003c\/strong\u003e of patients experienced a drug-related serious adverse event (“SAE”) in the safety analysis.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Competitors can present data, but replicating the quality and timing of Monopar's presentations requires similar clinical infrastructure.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ3 2024\u003c\/th\u003e\n\u003cth\u003eQ3 2025\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$984,278\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2,589,749\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents \u0026amp; Investments\u003c\/td\u003e\n\u003ctd\u003eData Not Explicitly Stated for Q3 2024 End\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$143.7 million\u003c\/strong\u003e (as of September 30, 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company is clearly organized to support this, with R\u0026amp;D expenses rising to support these efforts.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eR\u0026amp;D Expenses for Q3 2025 were \u003cstrong\u003e$2,589,749\u003c\/strong\u003e, an increase of \u003cstrong\u003e$1,605,471\u003c\/strong\u003e over Q3 2024.\u003c\/li\u003e\n\u003cli\u003eThe increase in R\u0026amp;D expenses is attributed to a \u003cstrong\u003e$937,582\u003c\/strong\u003e increase in manufacturing activities related to ALXN1840 and a \u003cstrong\u003e$617,667\u003c\/strong\u003e increase in R\u0026amp;D personnel expenses.\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents and investments as of September 30, 2025, were \u003cstrong\u003e$143.7 million\u003c\/strong\u003e, with expected runway through December 31, \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. This is an execution advantage that can be lost if a key trial misses its mark.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eMonopar Therapeutics Inc. (MNPR) - VRIO Analysis: 8. Expertise in Radiopharmaceutical Manufacturing and Logistics\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Successfully advancing MNPR-101-Lu into a Phase 1a trial requires specialized knowledge in manufacturing and handling radioisotopes, such as \u003cstrong\u003eLutetium-177\u003c\/strong\u003e (Lu-177).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e While the PRIT platform is unique, the operational know-how to manage the supply chain for therapeutic radioisotopes is scarce in smaller biotechs. A prior collaboration involved NorthStar Medical Radioisotopes for expertise in production, supply, and distribution of medical radioisotopes.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Manufacturing and logistics for radiopharmaceuticals are highly regulated and require specialized facilities or CROs, making it costly to imitate.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Investment in this operational backbone is suggested by increased R\u0026amp;D expenditures in Q3 2025, which included specific manufacturing activities.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ3 2025 Value\u003c\/th\u003e\n\u003cth\u003eQ3 2024 Value\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2,589,749\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$984,278\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIncrease Attributed to ALXN1840 Manufacturing\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$937,582\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Investments (as of Sep 30)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$143.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe increase in R\u0026amp;D expenses from Q3 2024 to Q3 2025 was \u003cstrong\u003e$1,605,471\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Operational expertise in a niche, regulated area like radiopharma manufacturing is a durable advantage.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMNPR-101-Lu Phase 1a trial active and recruiting in Australia as of October 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eMonopar Therapeutics Inc. (MNPR) - VRIO Analysis: 9. Intellectual Property Portfolio (Patents and Exclusivity)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The IP surrounding the MNPR-101 linker technology and the exclusivity for ALXN1840 provide a legal moat against direct competition for a defined period. The MNPR-101 program includes two issued U.S. composition of matter and their method of use patents, along with corresponding patents and applications in 22 foreign jurisdictions, including the European Union and Japan.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e The combination of composition-of-matter patents (for the linker technology) and market exclusivity for a rare disease drug (ALXN1840 for Wilson disease) is a powerful IP mix. The company is also actively filing provisional patents on new radiopharmaceutical compounds and linkers, with filings noted in April 2024 and October 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Patents offer the highest barrier to imitation, providing legal protection against competitors copying the core technology. The composition of matter claims on the linker family are designed to enhance stability and biodistribution of therapeutic radiopharmaceuticals.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company is actively managing its IP and financing strategy, as evidenced by filing a shelf registration statement on Form S-3 on August 29, 2025, to potentially fund future operations and IP expansion, with an initial maximum aggregate offering price of $300,000,000. Following a September 2025 offering, the company reported cash, cash equivalents, and investments of $143.7 million as of September 30, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Patents provide the strongest form of long-term protection, assuming they are broad and well-defended. The planned NDA submission for ALXN1840 in early 2026 will secure market exclusivity upon approval.\u003c\/p\u003e\n\u003cp\u003eThe intellectual property portfolio supports two key assets:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMNPR-101 Radiopharmaceuticals (uPAR-targeted): Includes clinical-stage MNPR-101-Zr (imaging), MNPR-101-Lu (therapeutic), and late-preclinical stage MNPR-101-Ac.\u003c\/li\u003e\n\u003cli\u003eALXN1840 (Wilson Disease): Acquired with an exclusive worldwide license, having completed Phase 3 trials.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe financial position as of September 30, 2025, was $143.7 million in cash, cash equivalents, and investments, expected to fund operations through at least December 31, 2027.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFinance: Sensitivity Analysis on Cash Runway Based on 6-Month NDA Filing Delay for ALXN1840\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe analysis is based on the reported Q3 2025 net loss of $3.43 million for the three months ending September 30, 2025.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eSource\/Basis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Investments (09\/30\/2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$143.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Runway End Date (Current)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eDecember 31, 2027\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Quarterly Operating Burn (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.43 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Monthly Operating Burn\u003c\/td\u003e\n\u003ctd\u003e$\\approx$ \u003cstrong\u003e$1.143 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e($3.43M \/ 3 months)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAssumed NDA Filing Delay\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6 Months\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUser Input\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Consumption for 6-Month Delay\u003c\/td\u003e\n\u003ctd\u003e$\\approx$ \u003cstrong\u003e$6.86 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e($1.143M\/month  6 months)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Runway End Date (With Delay)\u003c\/td\u003e\n\u003ctd\u003e$\\approx$ \u003cstrong\u003eJune 30, 2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e(December 31, 2027 minus 6 months)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe financial impact of a 6-month delay to the ALXN1840 NDA filing is an estimated consumption of approximately $6.86 million from the $143.7 million cash balance, effectively shortening the operational runway from December 31, 2027, to approximately June 30, 2027, assuming the operating burn rate remains consistent with Q3 2025 results.\u003c\/p\u003e\n\u003cp\u003eKey IP and Financial Milestones:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIssued U.S. Composition of Matter Patents for MNPR-101: 2\u003c\/li\u003e\n\u003cli\u003eForeign Jurisdictions with Patent Coverage for MNPR-101: 22\u003c\/li\u003e\n\u003cli\u003eShelf Registration Statement Filing Date: August 29, 2025\u003c\/li\u003e\n\u003cli\u003eGross Proceeds from September 2025 Offering (Net of Repurchase): $\\approx$ $100 million\u003c\/li\u003e\n\u003cli\u003eCash Position as of September 30, 2025: $143.7 million\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516209291413,"sku":"mnpr-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/mnpr-vrio-analysis.png?v=1740196470","url":"https:\/\/dcf-model.com\/pt\/products\/mnpr-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}